IMAC Holdings, Inc. acquired Assets of Theralink Technologies, Inc.
May 07, 2024
Share
IMAC Holdings, Inc. (NasdaqCM:BACK) acquired Assets of Theralink Technologies, Inc on May 1, 2024. As part of consideration IMAC Holdings, Inc agreement to issue certain shares of preferred stock of BACK to Theralink and/or certain holders of debt of Theralink, as applicable, in the future following the completion of a third party valuation of Theralink?s business.
IMAC Holdings, Inc. (NasdaqCM:BACK) completed the acquisition of Assets of Theralink Technologies, Inc on May 1, 2024.
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.
THERALINK TECHNOLOGIES, INC. 
